Becker's Healthcare June 21, 2024
Ashleigh Hollowell

Johnson & Johnson has completed its $850 million acquisition of Proteologix, a biologics company that specializes in developing treatments for immune-mediated diseases, it announced June 21.

While the acquisition allows the pharmaceutical giant to expand its immune-mediated disease pipeline, the acquisition of Proteologix will also broaden Johnson & Johnson’s atopic dermatitis treatment offerings.

“The Proteologix team has developed a promising early pipeline of bispecific antibodies that are a strong complement and strategic fit for our...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others
Weight Loss Drugs’ Effects Could Be Improved by Priming Melanocortin System
J&J IRA pricing offer is in, as it sticks with 2025 guidance

Share This Article